Cytek Biosciences, Inc. launches an IPO.

Cytek Biosciences is a leading company committed to providing powerful solutions for cell analysis, promoting next generation cell analysis tools and using new technology-based approaches. The company’s goal is to become the leader in cell analysis using regular innovations which favour scientific evidences in biomedical testings and clinical use.  

Capitalization after IPO is $2.250,00 billion.  

The IPO underwriters are Morgan Stanley, Goldman Sachs, Piper Sandler, Cowen